This is the FTSE 100’s worst-performing share over a year. I’m happy to own it!

This popular stock is the FTSE 100’s worst-performing share over 12 months. It’s crashed by a sixth (16.6%). Why do I keep buying it? Here’s the answer!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The past year has been pretty good for the FTSE 100 index. As I write, the Footsie stands at 6,919.88 points. On 14 April 2020, it closed at 5,791.30, hit by surging Covid-19 infections. Thus, the index is up almost 1130 points in 12 months — almost a fifth (19.5%). Of course, as a broad market index, the FTSE 100 tells us nothing about individual share successes and failures. Alas, my largest shareholding is the FTSE 100’s worst performer over the past year.

The FTSE 100 rebounds

As panic over Covid-19 gripped markets, global stock prices collapsed last spring. By 23 March, the FTSE 100 had plunged to a closing low of 4,993.89. However, thanks to massive monetary support from central banks and fiscal support from governments, optimism soon returned. Share prices soared, with this confidence continuing into this year. In 2021, the Footsie has already added almost 460 points (7.1%).

Over the past year, there have been huge variances in share performances within the FTSE 100. Good news: of the 101 stocks in the Footsie, no fewer than 89 have risen in value over 12 months. These uplifts range from a tiny 0.1% to an impressive 138.6%. Eight of these winning stocks have doubled or better since 14 April 2020. The average gain among these 89 winners is a tidy 45.5% (more than double the 19.5% gain of the wider index).

This is the Footsie’s biggest loser

At the other end of the scale lie 11 losers: the FTSE 100 shares that lost value over the past year. These losses range from just 0.5% to 16.6%, with the average loss coming to 7.4%. But these 11 losers include some real heavyweights, including a global bank, two giant oil companies, and a major pharmaceutical firm. Now for the bad news: shareholders of GlaxoSmithKline (LSE: GSK) own the FTSE 100’s worst-performing share over the past 12 months. I count myself among their number, as GSK is my biggest individual shareholding. Am I annoyed that the GSK share price has fallen by a sixth in a year? Yes! Am I rushing to sell? No! Here’s why.

I think the GSK share price is too cheap

As a young investor in the 1980s/90s, I would often make snap decisions, many of which backfired. After 35 years, I know to take stock before making considered decisions. So, why aren’t I selling the FTSE 100’s biggest loser today? Because I believe these shares to be undervalued and hence due a future re-rating. Also, having fallen over 30% from their 2020 peak (1,857p on 24 January 2020), I don’t see much more downside.

At the current share price of 1,295p, GSK shares trade on a price-to-earnings ratio of 11.26 with an earnings yield of 8.9%. But GSK is the world’s largest vaccine maker by revenue, so its 2020 earnings were depressed by routine vaccination programmes being abandoned during the pandemic. As Covid-19 recedes, these earnings should recover. Meanwhile, the steady 80p-per-share yearly cash payout equates to a dividend yield of 6.2% (almost double that of the wider FTSE 100).

GSK is undergoing rapid change and I do see some risks. It plans to split into two separate businesses in 2022 (BioPharma and Consumer Healthcare), which might hurt earnings. Also, the dividend is set to fall, which is bad news for income investors. And history suggests such radical corporate restructuring can have mixed results, often leading to worse returns. Nevertheless, while GSK’s stock trades at a big discount to the wider FTSE 100, I’ll keep buying more shares by reinvesting my juicy dividends.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

A 3-step passive income strategy to target major wealth

Want to invest in the stock market to build up a passive income stream? There's no fiendlishly complex multi-step mystique…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Should I buy Fundsmith Equity for my Stocks and Shares ISA?

Managed by Terry Smith -- often dubbed the UK’s Warren Buffett -- this £20bn fund remains a staple in many…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Down 5% despite good Q1 results, is now the time for investors to consider Sainsbury’s shares?

Supermarket giant Sainsbury’s released solid Q1 results on 1 July, but is down 5% from its one-year traded high, so…

Read more »

Electric cars charging in station
Investing Articles

Warren Buffett’s electric vehicle stock is smashing Tesla shares in 2025

Warren Buffett doesn’t get enough credit for owning this top-performing electric vehicle stock. In recent years, it’s been a brilliant…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s how investors could target £5,174 a year in passive income from £5,000 in savings invested in this FTSE 100 gem…

This often overlooked FTSE 100 savings and investment giant has an ultra-high yield of 8.4%, which can generate enormous passive…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

A profitable penny stock with a well-covered 8% dividend yield! What’s the catch?

Mark Hartley dives into a rare penny stock that offers an 8% dividend yield, investigating whether it deserves a place…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

I slashed my monthly expenses by £300 to help me aim for a steady second income stream of £20k

This Fool's saving an extra £300 a month and investing it in a portfolio of dividends stocks to power his…

Read more »

Workers at Whiting refinery, US
Investing Articles

Come on Shell! Here’s why you could consider buying BP shares…

Following takeover speculation, James Beard’s put together a letter to Shell’s boss explaining why the energy giant could consider buying…

Read more »